Green Cross and Nanolek announced that they have entered into a strategic partnership agreement for the commercialization of Green Cross' biologics in the Russian market. Under the terms of the agreement, Nanolek will obtain marketing authorizations and set up the production of a number of Green Cross' biologics. The production will be organized at Nanolek's facility, a biopharmaceutical complex built and equipped in compliance with EU GMP standards and launched in December 2014.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
14,620 KRW | -0.54% | -5.86% | -10.58% |
May. 03 | Green Cross Widens Q1 Loss, Sales Inch Up 2% | MT |
Mar. 20 | Green Cross Holdings Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
-10.58% | 491M | |
+38.51% | 728B | |
+33.05% | 603B | |
-6.23% | 360B | |
+18.78% | 332B | |
+1.35% | 279B | |
+16.00% | 244B | |
+8.09% | 207B | |
-5.77% | 205B | |
+6.19% | 164B |
- Stock Market
- Equities
- A005250 Stock
- News Green Cross Holdings Corporation
- Green Cross and Nanolek Announce Strategic Partnership for Biologics Commercialization in Russia